Galavit, rectal 50 mg 5 pcs

Pharmacotherapeutic group:

An immunomodulatory and anti-inflammatory agent.

TAC code: L03, G02.

Pharmacological properties:

Pharmacodynamics

The mechanism of action of the drug is associated with its ability to regulate

the functional and metabolic activity of cells of innate and adaptive immunity (monocytes, macrophages, neutrophils, natural killers, etc.). Galavit normalizes phagocytic activity of monocytes/ macrophages, bactericidal activity of neutrophils and cytotoxic activity of NK-cells.

With this, by restoring reduced activity of cells of innate and adaptive immunity, the preparation increases resistance of the body to infectious diseases.

In addition Galavit normalizes antibody formation and increases functional activity (affinity) of antibodies.

In case of inflammatory diseases the preparation reversibly inhibits for 6-8 hours the excessive synthesis by hyperactivated macrophages of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines the level of which determines the degree of inflammatory reactions, their

cyclic activity as well as the severity of intoxication of the body. Galavit decreases the production of reactive oxygen species by hyperactivated macrophages, thus reducing the level of oxidative stress and protecting tissues and organs from the damaging effects of radicals.

The drug has no allergizing, mutagenic, embryotoxic, teratogenic and carcinogenic action.

Pharmacokinetics: It is eliminated from the body mainly through the kidneys. After rectal administration the elimination half-life is 40-60 minutes. The main pharmacological effects are observed within 72 hours. Aminodihydrophthalazindione sodium in suppositories with rectal administration has high bioavailability due to which both local and expressed systemic effects are achieved.

Indications

Hepatitis, Urinary tract infections, Colds, Sore throat, Herpes, Periodontitis, Prevention of flu and colds, Bronchitis, Otitis, Boils, Stomach and duodenal ulcers, Intestinal infections, Inflammation in the mouth, Lung inflammation (pneumonia), Tonsillitis, Adenoids<> As an immunomodulatory and anti-inflammatory agent in children aged 6-12 years.p> As an immunomodulatory and anti-inflammatory agent in the treatment of children aged 6-12 years:

– frequent recurrent respiratory and ENT-organ diseases of bacterial and viral etiology (frequent acute respiratory infections, bronchitis, pneumonia, chronic tonsillitis, otitis media and adenoiditis);

– prevention of flu and acute respiratory infections;

– inflammatory diseases of the mucous membranes of the mouth and throat, periodontal disease;

– infectious intestinal diseases accompanied by intoxication and/or diarrhea;

– treatment and prevention of urogenital infections of bacterial and viral etiology;

– chronic recurrent diseases caused by herpes virus;

– diseases caused by the papillomavirus;

– gastric and 12 duodenal ulcer;

– viral hepatitis;

– purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy);

– postoperative purulent-septic complications and their prevention (including cancer patients);

– asthenic conditions, neurotic and somatoform disorders, reduced physical performance.

Active ingredient

Sodium aminodihydrophthalazindione

Composition

The active ingredient:

sodium aminodihydrophthalazindione (Galavit^â) 50 mg;

accessory substances:

Vitepsol W-35 (fatty acid glycerides) – 575 mg,

Vitepsol H-15 (fatty acid glycerides) – 575 mg.

How to take, the dosage

Rectally. The suppository is freed from the contoured package and then inserted into the rectum. It is recommended to free the intestines beforehand.

The dose and duration of use of the drug depends on the nature, severity and duration of the disease.

– With frequent recurrent respiratory and ENT diseases of bacterial and viral aetiology (frequent acute respiratory infections, bronchitis, pneumonia, chronic tonsillitis, otitis, adenoiditis): one suppository daily for 5 days, then one suppository every other day for 10 days. The course of 15 suppositories.

– For the prevention of influenza and acute respiratory infections: one suppository once a day. The course of 5 suppositories.

– In inflammatory diseases of the oral cavity and throat, periodontal diseases: the initial dose of 1 suppository daily – 5 suppositories, then one suppository at intervals of 72 hours. The course of 15 suppositories.

– In acute infectious intestinal diseases accompanied by diarrheal syndrome: the initial dose is 2 suppositories of 50 mg once and then 1 suppository 2 times a day until relief of intoxication symptoms. Subsequent continuation of the course of 1 suppository at intervals of 72 hours is possible. The course of 20 suppositories of 50 mg.

– In the treatment and prevention of urogenital infections of bacterial and viral etiology: 1 suppository 2 times a day, then 1 suppository every other day. The course of 10-15 suppositories (depending on the severity of the pathological process).

– In chronic recurrent diseases caused by the herpes virus: 1 suppository daily for 5 days, then 1 suppository every other day – 15 suppositories.

– In diseases caused by the papilloma virus: 5 days with 1 suppository once a day, then one suppository every other day. The course is 20 suppositories.

– In peptic ulcer disease of the stomach and 12 duodenal ulcer in the acute period: 2 days with 2 suppositories once a day, then 1 suppository with an interval of 72 hours. The course of 15-25 suppositories. In the chronic period: 5 days, 1 suppository 1 time a day, then 1 suppository 72 hours apart. The course of 20 suppositories.

– In viral hepatitis: the initial dose is 2 suppositories once, then one – 2 times a day until relief of symptoms of intoxication and inflammation. Subsequent continuation of the course of 1 suppository at intervals of 72 hours. The course of 20 suppositories.

– In purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, purulent pleurisy): 1 suppository daily-5 days, then 1 suppository every other day for 10 days.

– For prevention and treatment of surgical complications during the pre- and postoperative period (including cancer patients): 1 suppository 1 time daily – 5 suppositories before surgery, 5 suppositories after surgery – 1 every other day and 5 suppositories – at intervals of 72 hours. If the course of the disease is severe, the initial dose is 2 suppositories once or twice a day with one suppository. The course of treatment is 20 suppositories.

– With asthenic conditions, neurotic and somatoform disorders: 5 days one suppository daily, then one suppository every 72 hours. The course of 15 suppositories. To increase physical performance: 1 suppository every other day for a course of 5 suppositories.

If after treatment, no improvement or worsening of symptoms or new symptoms occur, it is necessary to consult a doctor. Use only with the directions, route of administration, and dosage listed in the directions for use.

Interaction

When concomitant use is possible to reduce the course doses of antibiotics. Cases of incompatibility with other drugs have not been reported.

Special Instructions

The indicated doses and duration of treatment should not be exceeded without consulting the attending physician.

Impact on the ability to drive vehicles and mechanisms:

The use of the drug Galavit^â suppositories rectal 50 mg does not affect the ability to drive vehicles, operate machinery and other activities requiring increased concentration and rapid psychomotor reactions.

Synopsis

The suppositories are white to white with a yellowish tint, torpedo-shaped with no visible blotches on the longitudinal slice.

Contraindications

Hypersensitivity to sodium aminodihydro-phthalazindione and other components of the drug, pregnancy and breastfeeding, children under 6 years of age.

.

Side effects

In rare cases, allergic reactions are possible.

Overdose

There have been no recorded cases of overdose.

Pregnancy use

The use of the drug is contraindicated in pregnancy and during breast-feeding.